BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 19900247)

  • 1. Economic data transferability for HTA: are we there yet?
    Manca A
    Value Health; 2009 Jun; 12(4):407. PubMed ID: 19900247
    [No Abstract]   [Full Text] [Related]  

  • 2. The transferability of economic data: a difficult endeavor.
    Sullivan SD
    Value Health; 2009 Jun; 12(4):408. PubMed ID: 19900248
    [No Abstract]   [Full Text] [Related]  

  • 3. 'HTA for Crisis': sharing experiences during the 7th EBHC Symposium.
    Wladysiuk M; Tabor A; Godman B
    Expert Rev Pharmacoecon Outcomes Res; 2013 Feb; 13(1):47-9. PubMed ID: 23402445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence-based decision-making 3: Health technology assessment.
    O'Reilly D; Campbell K; Vanstone M; Bowen JM; Schwartz L; Assasi N; Goeree R
    Methods Mol Biol; 2015; 1281():417-41. PubMed ID: 25694325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and Use of Disease-Specific (Reference) Models for Economic Evaluations of Health Technologies: An Overview of Key Issues and Potential Solutions.
    Frederix GW; Haji Ali Afzali H; Dasbach EJ; Ward RL
    Pharmacoeconomics; 2015 Aug; 33(8):777-81. PubMed ID: 25827099
    [No Abstract]   [Full Text] [Related]  

  • 6. [Health economics and HTA].
    Kulp W; Greiner W
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2006 Mar; 49(3):257-63. PubMed ID: 16465516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health technology assessment in Europe.
    Kristensen FB
    Scand J Public Health; 2009 Jun; 37(4):335-9. PubMed ID: 19493989
    [No Abstract]   [Full Text] [Related]  

  • 8. [Evaluation of medical methods--can we rely on cost-benefit-analysis?].
    Kristiansen IS; Stavem K; Linnestad K; Pedersen KM
    Tidsskr Nor Laegeforen; 2003 Mar; 123(5):657-60. PubMed ID: 12683199
    [No Abstract]   [Full Text] [Related]  

  • 9. Measurement of costs for health economic evaluation.
    Riewpaiboon A
    J Med Assoc Thai; 2014 May; 97 Suppl 5():S17-26. PubMed ID: 24964695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health economic decision-making: a comparison between UK and Spain.
    Corbacho B; Pinto-Prades JL
    Br Med Bull; 2012 Sep; 103(1):5-20. PubMed ID: 22833571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Health technology assessment (HTA). Developments in healthcare and potential for radiology].
    Gizewski ER; Forsting M; Krombach GA; Schöffski O
    Radiologe; 2014 Jun; 54(6):589-98. PubMed ID: 24844855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What decision-makers want and what they have been getting.
    McGregor M
    Value Health; 2006; 9(3):181-5. PubMed ID: 16689712
    [No Abstract]   [Full Text] [Related]  

  • 13. Advantages and disadvantages of discrete-event simulation for health economic analyses.
    Caro JJ; Möller J
    Expert Rev Pharmacoecon Outcomes Res; 2016 Jun; 16(3):327-9. PubMed ID: 26967022
    [No Abstract]   [Full Text] [Related]  

  • 14. Policy making and roles of health technology assessment.
    Tantivess S
    J Med Assoc Thai; 2008 Jun; 91 Suppl 2():S88-99. PubMed ID: 19253491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A determination of topics for health technology assessment in Thailand: making decision makers involved.
    Lertpitakpong C; Chaikledkaew U; Thavorncharoensap M; Tantivess S; Praditsitthikorn N; Youngkong S; Yothasamut J; Udomsuk K; Sinthitichai K; Teerawattananon Y
    J Med Assoc Thai; 2008 Jun; 91 Suppl 2():S100-9. PubMed ID: 19253492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reimbursement programs and health technology assessment for diabetes devices and supplies: a Canadian perspective.
    Cheung RY; Mui V
    J Diabetes Sci Technol; 2015 May; 9(3):706-10. PubMed ID: 25697719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IQWiG: an opportunity lost?
    Jönsson B
    Eur J Health Econ; 2008 Aug; 9(3):205-7. PubMed ID: 18496721
    [No Abstract]   [Full Text] [Related]  

  • 18. Resource modelling: the missing piece of the HTA jigsaw?
    Thokala P; Dixon S; Jahn B
    Pharmacoeconomics; 2015 Mar; 33(3):193-203. PubMed ID: 25411095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Defining the scope of health technology assessment and types of health economic evaluation.
    Tanvejsilp P; Ngorsuraches S
    J Med Assoc Thai; 2014 May; 97 Suppl 5():S10-6. PubMed ID: 24964694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic evaluation and health care decision-making.
    Rutten F
    Health Policy; 1996 Jun; 36(3):215-29. PubMed ID: 10158267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.